You are viewing the site in preview mode

Skip to main content

Advertisement

  • Correction
  • Open Access

Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

  • 1,
  • 2,
  • 2,
  • 3,
  • 3,
  • 4, 5,
  • 2,
  • 6,
  • 2,
  • 1,
  • 7,
  • 7,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 7 and
  • 1Email author
Contributed equally
Journal for ImmunoTherapy of Cancer20197:107

https://doi.org/10.1186/s40425-018-0469-9

  • Received: 27 November 2018
  • Accepted: 29 November 2018
  • Published:

The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:103

Correction to: J Immunother Cancer

https://doi.org/10.1186/s40425-018-0412-0

Following publication of the original article [1], the authors reported an error in their listed affiliations. This error was introduced during typesetting and the publisher apologizes to readers and the authors for the inconvenience.

In this Correction the authors are listed with their correct affiliations below.

Daniel H Johnson1, Chrystia M Zobniw2, Van A Trinh2, Junsheng Ma3, Roland L Bassett Jr3, Noha Abdel-Wahab4,5, Jaime Anderson2, Jennifer E Davis6, Jocelyn Joseph2, Marc Uemura1, Ali Noman7, Hamzah Abu-Sbeih7, Cassian Yee1, Rodabe Amaria1, Sapna Patel1, Hussein Tawbi1, Isabella C Glitza1, Michael A Davies1, Michael K Wong1, Scott Woodman1, Wen-Jen Hwu1, Patrick Hwu1, Yinghong Wang7 and Adi Diab1

1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2Division of Pharmacy, Clinical Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt

6Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

7Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(2)
Division of Pharmacy, Clinical Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(3)
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(4)
Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(5)
Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt
(6)
Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(7)
Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Reference

  1. Johnson DH, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6:103 https://doi.org/10.1186/s40425-018-0412-0.View ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement